213 related articles for article (PubMed ID: 20510203)
1. Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112.
Chen L; Pernazza D; Scott LM; Lawrence HR; Ren Y; Luo Y; Wu X; Sung SS; Guida WC; Sebti SM; Lawrence NJ; Wu J
Biochem Pharmacol; 2010 Sep; 80(6):801-10. PubMed ID: 20510203
[TBL] [Abstract][Full Text] [Related]
2. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor.
Chen L; Sung SS; Yip ML; Lawrence HR; Ren Y; Guida WC; Sebti SM; Lawrence NJ; Wu J
Mol Pharmacol; 2006 Aug; 70(2):562-70. PubMed ID: 16717135
[TBL] [Abstract][Full Text] [Related]
4. Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2.
Win-Piazza H; Schneeberger VE; Chen L; Pernazza D; Lawrence HR; Sebti SM; Lawrence NJ; Wu J
Cancer Lett; 2012 Jul; 320(1):81-5. PubMed ID: 22306001
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2.
Chen C; Cao M; Zhu S; Wang C; Liang F; Yan L; Luo D
Sci Rep; 2015 Dec; 5():17626. PubMed ID: 26626996
[TBL] [Abstract][Full Text] [Related]
6. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).
Zhang X; He Y; Liu S; Yu Z; Jiang ZX; Yang Z; Dong Y; Nabinger SC; Wu L; Gunawan AM; Wang L; Chan RJ; Zhang ZY
J Med Chem; 2010 Mar; 53(6):2482-93. PubMed ID: 20170098
[TBL] [Abstract][Full Text] [Related]
7. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
Romero C; Lambert LJ; Sheffler DJ; De Backer LJS; Raveendra-Panickar D; Celeridad M; Grotegut S; Rodiles S; Holleran J; Sergienko E; Pasquale EB; Cosford NDP; Tautz L
J Biol Chem; 2020 Feb; 295(9):2601-2613. PubMed ID: 31953320
[TBL] [Abstract][Full Text] [Related]
8. Identification of demethylincisterol A
Chen C; Liang F; Chen B; Sun Z; Xue T; Yang R; Luo D
Eur J Pharmacol; 2017 Jan; 795():124-133. PubMed ID: 27939989
[TBL] [Abstract][Full Text] [Related]
9. Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).
Liu W; Yu B; Xu G; Xu WR; Loh ML; Tang LD; Qu CK
J Med Chem; 2013 Sep; 56(18):7212-21. PubMed ID: 23957426
[TBL] [Abstract][Full Text] [Related]
10. Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2.
Chio CM; Lim CS; Bishop AC
Biochemistry; 2015 Jan; 54(2):497-504. PubMed ID: 25519989
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds.
Lawrence HR; Pireddu R; Chen L; Luo Y; Sung SS; Szymanski AM; Yip ML; Guida WC; Sebti SM; Wu J; Lawrence NJ
J Med Chem; 2008 Aug; 51(16):4948-56. PubMed ID: 18680359
[TBL] [Abstract][Full Text] [Related]
12. Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation.
Sha F; Kurosawa K; Glasser E; Ketavarapu G; Albazzaz S; Koide A; Koide S
J Mol Biol; 2023 Apr; 435(8):168010. PubMed ID: 36806475
[TBL] [Abstract][Full Text] [Related]
13. SHP2E76K mutant promotes lung tumorigenesis in transgenic mice.
Schneeberger VE; Luetteke N; Ren Y; Berns H; Chen L; Foroutan P; Martinez GV; Haura EB; Chen J; Coppola D; Wu J
Carcinogenesis; 2014 Aug; 35(8):1717-25. PubMed ID: 24480804
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells.
Raveendra-Panickar D; Finlay D; Layng FI; Lambert LJ; Celeridad M; Zhao M; Barbosa K; De Backer LJS; Kwong E; Gosalia P; Rodiles S; Holleran J; Ardecky R; Grotegut S; Olson S; Hutchinson JH; Pasquale EB; Vuori K; Deshpande AJ; Cosford NDP; Tautz L
J Biol Chem; 2022 Jan; 298(1):101477. PubMed ID: 34896393
[TBL] [Abstract][Full Text] [Related]
15. Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor.
Ren Y; Meng S; Mei L; Zhao ZJ; Jove R; Wu J
J Biol Chem; 2004 Feb; 279(9):8497-505. PubMed ID: 14665621
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma.
Schneeberger VE; Ren Y; Luetteke N; Huang Q; Chen L; Lawrence HR; Lawrence NJ; Haura EB; Koomen JM; Coppola D; Wu J
Oncotarget; 2015 Mar; 6(8):6191-202. PubMed ID: 25730908
[TBL] [Abstract][Full Text] [Related]
17. Induction of a tumor-associated activating mutation in protein tyrosine phosphatase Ptpn11 (Shp2) enhances mitochondrial metabolism, leading to oxidative stress and senescence.
Zheng H; Li S; Hsu P; Qu CK
J Biol Chem; 2013 Sep; 288(36):25727-25738. PubMed ID: 23884424
[TBL] [Abstract][Full Text] [Related]
18. Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation.
Liu WS; Jin WY; Zhou L; Lu XH; Li WY; Ma Y; Wang RL
J Comput Aided Mol Des; 2019 Aug; 33(8):759-774. PubMed ID: 31300938
[TBL] [Abstract][Full Text] [Related]
19. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer.
Rehman AU; Rahman MU; Khan MT; Saud S; Liu H; Song D; Sultana P; Wadood A; Chen HF
Curr Pharm Des; 2018; 24(32):3767-3777. PubMed ID: 30398108
[TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening.
Yu ZH; Chen L; Wu L; Liu S; Wang L; Zhang ZY
Bioorg Med Chem Lett; 2011 Jul; 21(14):4238-42. PubMed ID: 21669525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
